Hobson, James ORCID: 0000-0003-2551-1774, Savage, Alison ORCID: 0000-0002-5312-9946, Dwyer, Andrew, Unsworth, Catherine, Arshad, Usman ORCID: 0000-0003-1586-1885, Pertinez, Henry, box, helen, Tatham, Lee ORCID: 0000-0001-9448-8876, Rajoli, Rajith ORCID: 0000-0002-6015-5712, Neary, Megan ORCID: 0000-0002-4960-2139 et al (show 8 more authors)
(2021)
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection.
Unknown.
Abstract
The spread of SARS-CoV-2 across the world requires the formation of a range of interventions that include immunomodulatory or antiviral therapeutics and repurposing of existing drug compounds is an important strategy to rapidly identify possible options. Niclosamide is a cheap and generic drug compound with a proven in vitro ability to inhibit viral replication of SARS-CoV-2; this drug also has known poor oral bioavailability due to very low water solubility. Here, we demonstrate the nanoparticle formulation of niclosamide using a new, cheap and scalable process to enable long-acting injectable administration and show extended circulating drug exposure in vivo over 28 days using a rodent model after depot injection.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Lung, Pneumonia, Emerging Infectious Diseases, Prevention, Biodefense, Vaccine Related, 5.1 Pharmaceuticals, 5 Development of treatments and therapeutic interventions, Infection, 3 Good Health and Well Being |
Depositing User: | Symplectic Admin |
Date Deposited: | 29 Jan 2021 11:33 |
Last Modified: | 11 Apr 2024 16:38 |
DOI: | 10.26434/chemrxiv.13587035.v1 |
Open Access URL: | https://doi.org/10.26434/chemrxiv.13587035.v1 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3114960 |